UCB Share Price Other OTC
Stocks
UCBJF
BE0003739530
Pharmaceuticals
OTC Markets Traded| Market Cap | 42.57B 49.03B 39.7B 36.47B 68.97B 4,664B 69.72B 468B 183B 2,332B 184B 180B 7,725B | P/E 2026 * |
22.8x | P/E 2027 * | 18.5x |
|---|---|---|---|---|---|
| Enterprise Value | 42.79B 49.28B 39.9B 36.65B 69.32B 4,688B 70.08B 470B 184B 2,343B 185B 181B 7,764B | EV / Sales 2026 * |
4.95x | EV / Sales 2027 * | 4.19x |
| Free-Float |
61.59% | Yield 2026 * |
0.65% | Yield 2027 * | 0.67% |
Last Transcript: UCB
| 1 day | -0.39% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 67 | 31/12/2014 | |
Sandrine Dufour
DFI | Director of Finance/CFO | 60 | 30/06/2020 |
Alistair Henry
CTO | Chief Tech/Sci/R&D Officer | 59 | 30/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 31/12/2011 | |
| Director/Board Member | 67 | 31/12/2014 | |
| Director/Board Member | 56 | 23/04/2014 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.39% | -.--% | - | - | 49.03B | |
| +0.19% | +9.42% | +33.09% | -0.75% | 75.96B | |
| +3.72% | -4.71% | -8.40% | +20.60% | 47.88B | |
| +1.42% | +2.02% | -51.10% | -50.16% | 43.39B | |
| +3.29% | +1.38% | +57.68% | -22.49% | 30.8B | |
| +1.83% | -7.18% | +54.54% | +89.53% | 24.45B | |
| +3.36% | +2.12% | +106.19% | -47.32% | 22.75B | |
| +4.15% | +0.67% | -8.56% | +210.84% | 19.24B | |
| +1.35% | -6.42% | +61.02% | +118.77% | 15.87B | |
| +2.64% | -4.07% | +71.87% | +162.62% | 16.04B | |
| Average | +1.98% | -0.10% | +35.15% | +53.52% | 32.93B | |
| Weighted average by Cap. | +1.71% | +2.43% | +24.89% | +26.06% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.64B 9.96B 8.06B 7.4B 14B 947B 14.16B 95.02B 37.15B 473B 37.39B 36.57B 1,569B | 9.7B 11.17B 9.04B 8.31B 15.71B 1,063B 15.89B 107B 41.68B 531B 41.95B 41.03B 1,760B |
| Net income | 1.86B 2.14B 1.74B 1.59B 3.02B 204B 3.05B 20.46B 8B 102B 8.05B 7.87B 338B | 2.34B 2.69B 2.18B 2B 3.79B 256B 3.83B 25.69B 10.04B 128B 10.11B 9.88B 424B |
| Net Debt | 216M 248M 201M 185M 349M 23.62B 353M 2.37B 927M 11.81B 933M 912M 39.13B | -1.9B -2.19B -1.77B -1.63B -3.07B -208B -3.11B -20.86B -8.15B -104B -8.21B -8.03B -344B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
